Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Phase 3 Unknown 50 enrolled Zhengang Yuan

Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study evaluates the efficacy and safety of second-line treatment of bortezomib in advanced intrahepatic cholangiocarcinoma patients.Half of participants will receive bortezomib while the other half will receive best supporting care.

Timeline

Start: 2017-01
Primary completion: 2020-12
Completion: 2022-12

Publications

Zeng TM, Jiang TY, Yang G, Cheng Z, Lou C, Wei W, Tao CJ, Hu S, Wang H, Cui XW, Tan YX, Dong LW, Wang HY, Yuan ZG. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial. Clin Transl Med. 2024 May;14(5):e1675. doi: 10.1002/ctm2.1675.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	—

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Summary

Timeline

Publications

Drugs

Indications